A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
← catalyst calendarNCT06319456 · readout ≤ 376 d
Sponsored by Ascentage Pharma Group Inc. (industry) · AAPG — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
344estimated
Sites
10
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-07 | actual | When the study began enrolling |
| Primary completion | Aug 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2024-03-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- CLL/SLL
Interventions
- Drug: Lisaftoclax (APG-2575)
- Drug: Acalabrutinib
- Drug: Fludarabine
- Drug: Cyclophosphamide，CTX
- Drug: Rituximab
- Drug: Chlorambucil
Primary outcome
what the primary-completion date above is the date OFProgress Free Survival (PFS)
measured Up to 1 year
Permalink · AAPG's whole pipeline · Catalyst calendar · Every registered study · What changed